Ferdinando Riccardi - Azienda Ospedaliera Antonio Cardarelli

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 160 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Epidemiology of Gastroenteropancreatic Neuroendocrine Neoplasms: a Review and Protocol Presentation for Bridging Tumor Registry Data with the Italian Association for Neuroendocrine Tumors (itanet) National Database

Endocrineno. 1 (2024): 42-47

Cited0Views0WOSBibtex

HER2 Immunohistochemistry (IHC) Expression in HER2-positive (her2pos) Metastatic Breast Cancer (mbc): Clinical and Prognostic Differences Between IHC 2+and IHC 3+Populations

Arianna Dri,Eva Blondeaux,Claudia Bighin, Simona Gasparro,Stefania Russo, Lorenzo Foffano, Palma Pugliese,Andrea Fontana,Enrico Cortesi,Antonella Ferzi,Ferdinando Riccardi,Valentina Sini,Luca Boni,Alessandra Fabi, Filippo Montemurro, Michelino De Laurentiis,Grazia Arpino, Lucia Del Mastro, Lorenzo Gerratana, Fabio Puglisi

CANCER RESEARCHno. 9 (2024)

Cited0Views0Bibtex

The Journey of Patients Affected by Metastatic Hormone Receptor-Positive/her2-negative Breast Cancer from CDK 4/6 Inhibitors to Second-Line Treatment: a Real-World Analysis of 701 Patients Enrolled in the GIM14/BIOMETA Study

Chiara Molinelli, Marco Bruzzone, Eva Blondeaux, Tommaso Ruelle, Chiara Lanzavecchia, Michelino De Laurentiis, Stefania Russo,Ferdinando Riccardi, Valentina Sini,Francesco Cognetti, Grazia Arpino,Alessandra Fabi, Palma Pugliese, Elena Collovà,Andrea Fontana, Fabio Puglisi, Claudia Bighin, Matteo Lambertini, Lucia Del Mastro

European journal of cancer (Oxford, England 1990) (2024): 115113-115113

Cited0Views0WOSBibtex

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

CANCERS（2024）

Cited0Views0WOSBibtex

Adjuvant Endocrine Therapy Choices in Premenopausal Patients with Hormone Receptor-Positive Early Breast Cancer: Insights from the Prospective GIM23-POSTER Study

Luca Arecco,Maria Maddalena Latocca,Eva Blondeaux,Ferdinando Riccardi,Carmela Mocerino,Valentina Guarneri,Eleonora Mioranza,Giancarlo Bisagni,Elisa Gasparini,Fabio Puglisi, Alexandro Membrino,Antonella Ferro,Vincenzo Adamo,Filippo Giovanardi,Stefano Tamberi,Sara Donati,Elisabetta Landucci,Laura Biganzoli, Sara Piccinini,Simona Pastorino,Evandro de Azambuja,Francesca Poggio, Matteo Lambertini, Lucia Del Mastro

BREAST (2024)

Cited0Views0WOSBibtex

LBA2 First-line (1L) Durvalumab (D) + Platinum-Etoposide (EP) for Patients (pts) with Extensive-Stage SCLC (ES-SCLC): Primary Results from the Phase IIIb LUMINANCE Study

N. Reinmuth,M. Özgüroğlu,N.B. Leighl,D. Galetta,I. Hacibekiroglu,J. Roubec,M.A.N. Sendur,E. Bria,I. Cicin,C. Grohé,H. Harputluoglu,S. Kilickap,S. Novello,P. Opalka,F. Riccardi, R.K. Ruseva, S. Lang, M. Hodari,N. Donner,F. de Marinis

Immuno-Oncology and Technology (2023): 100692

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn